MA46954A - Méthodes de traitement d'états inflammatoires - Google Patents

Méthodes de traitement d'états inflammatoires

Info

Publication number
MA46954A
MA46954A MA046954A MA46954A MA46954A MA 46954 A MA46954 A MA 46954A MA 046954 A MA046954 A MA 046954A MA 46954 A MA46954 A MA 46954A MA 46954 A MA46954 A MA 46954A
Authority
MA
Morocco
Prior art keywords
methods
inflammatory conditions
treating inflammatory
treating
conditions
Prior art date
Application number
MA046954A
Other languages
English (en)
Inventor
Jeanne Allinne
Andrew J Murphy
Jamie M Orengo
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA46954A publication Critical patent/MA46954A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
MA046954A 2016-12-01 2017-11-30 Méthodes de traitement d'états inflammatoires MA46954A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428634P 2016-12-01 2016-12-01
US201762473738P 2017-03-20 2017-03-20
US201762567318P 2017-10-03 2017-10-03

Publications (1)

Publication Number Publication Date
MA46954A true MA46954A (fr) 2019-10-09

Family

ID=60788696

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046954A MA46954A (fr) 2016-12-01 2017-11-30 Méthodes de traitement d'états inflammatoires

Country Status (22)

Country Link
US (4) US10815305B2 (fr)
EP (1) EP3548513A1 (fr)
JP (4) JP7132220B2 (fr)
KR (3) KR20250040088A (fr)
CN (2) CN118662629A (fr)
AU (2) AU2017367691B2 (fr)
BR (1) BR112019010646A2 (fr)
CA (1) CA3044851A1 (fr)
CL (1) CL2019001475A1 (fr)
CO (1) CO2019005236A2 (fr)
CR (1) CR20190311A (fr)
IL (1) IL266770B2 (fr)
MA (1) MA46954A (fr)
MX (2) MX2019006177A (fr)
MY (1) MY200433A (fr)
NZ (1) NZ794842A (fr)
PH (1) PH12019501120A1 (fr)
TN (1) TN2019000172A1 (fr)
TW (2) TWI784988B (fr)
UA (1) UA127965C2 (fr)
WO (1) WO2018102597A1 (fr)
ZA (1) ZA201903091B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
WO2017189805A1 (fr) 2016-04-27 2017-11-02 Abbvie Inc. Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
WO2018231827A1 (fr) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anticorps anti-il1rap et conjugués anticorps-médicament
US11034768B2 (en) * 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CA3087063A1 (fr) 2017-12-29 2019-07-04 Cornell University Therapie genique pour les maladies eosinophiliques
US11352562B2 (en) 2018-04-10 2022-06-07 Showa Denko Materials Co., Ltd. Epoxy resin, epoxy resin composition, epoxy resin cured product and composite material
IL307286B2 (en) * 2018-04-11 2026-03-01 Regeneron Pharma Methods and compositions for quantifying il-33
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
WO2020150633A1 (fr) * 2019-01-18 2020-07-23 Orthobio Therapeutics, Inc. Édition de gène pour améliorer la fonction articulaire
TWI861073B (zh) * 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
MX2021013427A (es) * 2019-05-01 2022-01-31 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2021068196A1 (fr) * 2019-10-11 2021-04-15 General Regeneratives (Shanghai) Limited Procédés d'utilisation de la protéine il-33 dans le traitement de cancers
KR20220092927A (ko) * 2019-11-04 2022-07-04 메디뮨 리미티드 신장 장애를 치료하기 위한 항 il-33 치료제
CN114786775A (zh) * 2019-12-06 2022-07-22 赛诺菲生物技术公司 通过施用il-33拮抗剂治疗copd的方法
US20230340101A1 (en) * 2019-12-23 2023-10-26 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
JP2023516497A (ja) 2020-03-13 2023-04-19 メドイミューン・リミテッド Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
CN115867575A (zh) 2020-04-06 2023-03-28 免疫医疗有限公司 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
TWI899211B (zh) 2020-04-17 2025-10-01 小利蘭史丹佛大學董事會 用於生物醫藥調配物之聚合物賦形劑
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
JP7578943B2 (ja) * 2020-07-13 2024-11-07 学校法人自治医科大学 褥瘡治療剤
CN111714619B (zh) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用
EP4267614A1 (fr) * 2020-12-23 2023-11-01 Numab Therapeutics AG Domaines variables d'anticorps se liant à il-31
CN117858898A (zh) * 2021-08-27 2024-04-09 免疫医疗有限公司 用抗白介素-33抗体治疗慢性阻塞性肺病
EP4430211A1 (fr) * 2021-11-11 2024-09-18 Regeneron Pharmaceuticals, Inc. Traitement des maladies pulmonaires en fonction de la stratification du score de risque polygénique pour l'interleukine 33 (il-33)
JP7544228B2 (ja) 2022-10-31 2024-09-03 トヨタ自動車株式会社 車両制御システム、車両製造方法、プログラム及び情報処理装置
CN121079320A (zh) * 2023-02-28 2025-12-05 科达制药股份有限公司 多价trap-抗体融合体
US20240360232A1 (en) * 2023-03-22 2024-10-31 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
CN120118185B (zh) * 2025-03-11 2025-08-26 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种猫过敏原Fel d 1蛋白单克隆抗体及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
EP0668774A1 (fr) 1991-05-03 1995-08-30 Seragen, Inc. Molecules ciblees sur un recepteur de l'interleukine destinees a traiter l'arthrite inflammatoire
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (fr) 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US5576191A (en) 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (fr) 2001-05-11 2002-11-21 Novartis Ag Compositions permettant de traiter les troubles associes aux ige
CA2447795A1 (fr) 2001-05-23 2002-11-28 Duotol Ab Suppression de reactions allergiques par administration intradermique d'allergenes conjugues avec des sous unites de toxine ou des fragments de celle-ci
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
WO2004070010A2 (fr) 2003-02-01 2004-08-19 Tanox, Inc. Procede destine a produire des anticorps a affinite elevee
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2005085284A1 (fr) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006083390A2 (fr) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxine-3 dans l'oesophagite eosinophile
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8865645B2 (en) 2006-05-24 2014-10-21 Biogen Idec Ma Inc. Method of treating lung fibrosis using ST2 polypeptide
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (fr) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. Anticorps humains a haute affinite vis-a-vis du recepteur il-4 humain
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2022507A1 (fr) 2007-08-07 2009-02-11 Universität Hamburg Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP2011500748A (ja) 2007-10-26 2011-01-06 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 神経変性障害の治療におけるｃａｓｐａｓｅＩ−依存性サイトカインの阻害剤
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2748712A1 (fr) 2008-12-01 2010-06-10 Children's Hospital Medical Center Procedes de determination de l'efficacite d'un traitement par glucocorticoide de l'esophagite a eosinophiles
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
EP2475388B1 (fr) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Utilisation d'antagonistes de l'il-33 à des fins de traitement des maladies fibrotiques
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
US20130324435A1 (en) 2011-01-06 2013-12-05 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
ES2549637T3 (es) 2011-02-23 2015-10-30 F. Hoffmann-La Roche Ag Anticuerpos contra IL33R humano y la utilización de los mismos
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
WO2013155010A1 (fr) 2012-04-09 2013-10-17 Children's Hospital Medical Center Biomarqueurs non invasifs pour l'œsophagite éosinophile
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) * 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) * 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
NO2785538T3 (fr) 2014-05-07 2018-08-04
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法

Also Published As

Publication number Publication date
KR20250040088A (ko) 2025-03-21
IL266770B2 (en) 2023-10-01
JP7132220B2 (ja) 2022-09-06
AU2024278257A1 (en) 2025-01-09
KR20240033187A (ko) 2024-03-12
AU2017367691A1 (en) 2019-06-20
US20240209102A1 (en) 2024-06-27
CN110167963B (zh) 2024-06-14
BR112019010646A2 (pt) 2019-10-01
CN110167963A (zh) 2019-08-23
TWI857389B (zh) 2024-10-01
MX2023008368A (es) 2023-07-26
CL2019001475A1 (es) 2019-08-16
UA127965C2 (uk) 2024-02-28
KR102645242B1 (ko) 2024-03-13
JP2022174089A (ja) 2022-11-22
IL266770B1 (en) 2023-06-01
TWI784988B (zh) 2022-12-01
MY200433A (en) 2023-12-26
WO2018102597A1 (fr) 2018-06-07
KR20190086471A (ko) 2019-07-22
JP2026016421A (ja) 2026-02-03
JP2020513404A (ja) 2020-05-14
CA3044851A1 (fr) 2018-06-07
ZA201903091B (en) 2025-04-30
KR102780485B1 (ko) 2025-03-14
CN118662629A (zh) 2024-09-20
US12624114B2 (en) 2026-05-12
EP3548513A1 (fr) 2019-10-09
CO2019005236A2 (es) 2019-05-31
CR20190311A (es) 2019-08-20
MX2019006177A (es) 2019-08-29
TN2019000172A1 (en) 2020-10-05
NZ754300A (en) 2025-11-28
US10815305B2 (en) 2020-10-27
US20180155436A1 (en) 2018-06-07
JP7351989B2 (ja) 2023-09-27
NZ794842A (en) 2026-03-27
US20260193369A1 (en) 2026-07-09
US20210079105A1 (en) 2021-03-18
JP2023175785A (ja) 2023-12-12
IL266770A (en) 2019-07-31
TW201827079A (zh) 2018-08-01
AU2017367691B2 (en) 2024-09-26
US11866503B2 (en) 2024-01-09
PH12019501120A1 (en) 2019-08-19
TW202332696A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3478286A4 (fr) Méthodes de traitement du cancer de l'ovaire
IL266770A (en) Methods for treating inflammatory conditions
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3288383A4 (fr) Méthodes de traitement du cancer
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
MA45192A (fr) Traitement d'association
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
EP3500289A4 (fr) Procédés de traitement de la trachéobronchomalacie
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3402572A4 (fr) Compositions et méthodes de traitement d'états inflammatoires allergiques
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3324961A4 (fr) Méthodes de traitement de troubles du développement avec le gaboxadol
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3440112A4 (fr) Méthodes de traitement du cancer
EP3380095A4 (fr) Compositions et méthodes de traitement d'un avc ischémique
EP3773633A4 (fr) Méthodes de traitement de glioblastomes